Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19894190 | 1.00 | ABCB1 (0.44) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL23552861 | 0.99 | ABCB1 (0.45) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL1238420 | 0.90 | ABCB1 (0.46) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL1238418 | 0.90 | ABCB1 (0.46) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL23461642 | 0.90 | AGTR2 (0.46) | ABCB1MCL1KLK7UCHL1LIPG | |
| SCHEMBL18093988 | 0.90 | ABCB1 (0.52) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL475487 | 0.90 | ABCB1 (0.52) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL3854950 | 0.90 | ABCB1 (0.52) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL475486 | 0.90 | ABCB1 (0.52) | ABCB1MCL1KLK7UCHL1P2RX3 | |
| SCHEMBL3191348 | 0.90 | ABCB1 (0.52) | ABCB1MCL1KLK7UCHL1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286169-B1 | PROTAC COMPOUNDS MODULATING RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3286169-B1 | PROTAC COMPOUNDS MODULATING RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10435391-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-10435391-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435391-B2 | Compounds | RIPK2, RIPK1, RIPK4 | ABCB1 2402/4885MCL1 972/4885KLK7 3981/4885 |
| US-20180134688-A1 | NOVEL COMPOUNDS | RIPK2, RIPK1, RIPK4 | ABCB1 2761/4885MCL1 986/4885KLK7 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.